| Literature DB >> 27445466 |
Francisco José Tarazona-Santabalbina1, Ángel Belenguer-Varea1, Eduardo Rovira1, David Cuesta-Peredó1.
Abstract
Hip fractures are a very serious socio-economic problem in western countries. Since the 1950s, orthogeriatric units have introduced improvements in the care of geriatric patients admitted to hospital because of hip fractures. During this period, these units have reduced mean hospital stays, number of complications, and both in-hospital mortality and mortality over the middle term after hospital discharge, along with improvements in the quality of care and a reduction in costs. Likewise, a recent clinical trial has reported greater functional gains among the affected patients. Studies in this field have identified the prognostic factors present upon admission or manifesting themselves during admission and that increase the risk of patient mortality or disability. In addition, improved care afforded by orthogeriatric units has proved to reduce costs. Nevertheless, a number of management issues remain to be clarified, such as the optimum anesthetic, analgesic, and thromboprophylactic protocols; the type of diagnostic and therapeutic approach best suited to patients with cognitive problems; or the efficiency of the programs used in convalescence units or in home rehabilitation care. Randomized clinical trials are needed to consolidate the evidence in this regard.Entities:
Keywords: geriatric assessment; hip fractures; mortality; orthogeriatric care; recovery of function
Mesh:
Year: 2016 PMID: 27445466 PMCID: PMC4928624 DOI: 10.2147/CIA.S72436
Source DB: PubMed Journal: Clin Interv Aging ISSN: 1176-9092 Impact factor: 4.458
Figure 1Flow chart study selection procedure used in literature search.
Summary of the some most relevant studies included in this review
| Authors | Year | Country | Sample size | Inclusion criteria | Exclusion criteria | Study design | Conclusion summary | Level of evidence |
|---|---|---|---|---|---|---|---|---|
| Brunskill et al | 2015 | UK | Six studies (2,722 participants) | Randomized controlled trials comparing red blood cell transfusion versus no transfusion or an alternative to transfusion, different transfusion protocols, or different transfusion thresholds in hip fracture patients | None specified | Meta-analysis | Liberal versus restricted threshold transfusion: no differences in mortality, at 30 days post-hip fracture surgery (RR 0.92, 95% CI 0.67–1.26) or at 60 days postsurgery (RR 1.08, 95% CI 0.80–1.44); no difference in functional recovery at 60 days; very low-quality evidence of a lower risk of myocardial infarction in the liberal transfusion threshold group (RR 0.59, 95% CI 0.36–0.96) | IA |
| Liu et al | 2015 | People’s Republic of China | Ten studies (986 patients) | Hip fracture | 1) Patients with multiple systemic fractures or pathologic fractures; 2) data without standard deviations; 3) participants with hip fractures who had undergone nonsurgical treatment | Meta-analysis | Perioperative oral nutritional supplementation: higher total protein levels (SMD =1.56 [95% CI 1.06, 2.07]; | IA |
| Prestmo et al | 2015 | Norway | 1,077 patients | Hip fracture patients | None specified | Clinical trial | Functional recovery; mean SPPB scores at 4 months were 5.12 (SE 0.20) for comprehensive geriatric care and 4.38 (SE 0.20) for orthopedic care (between-group difference 0.74, 95% CI 0.18–1.30, | IB |
| Mazzola et al | 2015 | Italy | 275 patients | Hip fracture patients and comorbidity or multiple-drug treatment or use of oral anticoagulants or lack of social support | None specified | Longitudinal cohort study | 6-month mortality factors: severe disability (OR 2.24, 95% CI 1.08–4.65) and postoperative delirium (OR 3.80, 95% CI 1.72–8.39) | IIB |
| Grigoryan et al | 2014 | US | 18 studies (9,094 patients) | Hip fracture studies Orthogeriatric multidisciplinary approach | Not English or Spanish studies; not control group studies; published as an abstract or letter; or published >20 years prior to the search period | Meta-analysis | Reduction of in-hospital mortality (RR 0.60; 95% CI 0.43, 0.84) and long-term mortality (RR 0.83; 95% CI 0.74, 0.94); reduction of length of stay (SMD −0.25; 95% CI −0.44, −0.05), particularly in the shared care model (SMD −0.61; 95% CI −0.95, −0.28) | IA |
| Taraldsen et al | 2014 | Norway | 317 patients | Hip fracture patients previously living in their own homes and able to walk 10 m | Patient with pathological fractures, multitrauma injuries, or short life expectancy | Clinical trial | Comprehensive geriatric care; better SPPB score, 1.6 (SD 2.0) versus 1.0 (SD 1.6); | IB |
| Moja et al | 2012 | Italy | 35 studies (191,873 patients) | Hip fracture patients aged ≥65 years | None specified | Meta-analysis | Early hip surgery (1–2 days); lower risk of death (OR 0.74 [95% CI 0.67–0.81, | IA |
| Stenvall et al | 2012 | Sweden | 64 patients | Hip fracture | Rheumatoid arthritis, severe hip osteoarthritis, severe renal failure, pathological fracture, and being bedridden before the fracture | Clinical trial | Fewer postoperative complications in the intervention group: urinary tract infections 6 (21%) versus 23 (64%), | IB |
| Carson et al | 2011 | US | 2,016 patients | Hip fracture patients with clinical evidence of or risk factors for cardiovascular disease | Unable to walk without human assistance before hip fracture, declined blood transfusions, multiple trauma, pathologic hip fracture associated with cancer, acute myocardial infarction 30 days before randomization, symptoms associated with anemia, actively bleeding at the time of potential randomization | Clinical trial | Blood transfusion (OR in the liberal strategy group 1.01; 95% CI 0.84–1.22), absolute risk difference of 0.5 percentage points (95% CI −3.7–4.7); in-hospital acute coronary syndrome (absolute risk difference −0.9%; 99% CI −3.3–1.6), and death on 60-day follow-up (absolute risk difference 1.0%; 99% CI −1.9–4.0) | IB |
| Simunovic et al | 2010 | Canada | Five observational studies (n=4,208) | Hip fracture patients | None | Meta-analysis | Earlier surgery; lower mortality risk (RR 0.81, 95% CI 0.68–0.96, | IA |
Notes: Levels of evidence for therapeutic studies: IA, systematic review (with homogeneity) of RCTs; IB, individual RCT (with narrow confidence intervals); IIB, individual cohort study (including low quality RCT, eg, <80% follow-up); II, small RCTs with unclear results.
Abbreviations: RR, risk ratio; CI, confidence interval; OR, odds ratio; SPPB, Short Physical Performance Battery; SE, standard error; SD, standard deviation; SMD, standard mean difference; RR, relative risk; RCT, randomized control trials.